Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis.

European journal of cancer (Oxford, England : 1990) - 1 Aug 2017

Valachis Antonis, Ullenhag Gustav J

Abstract excerpt

The incidence of malignant melanoma is growing rapidly. Approximately half of the cases are BRAF mutated, making treatment with kinase inhibitors a (MEK and BRAF inhibitors) preferred choice in the advanced setting. The vast majority of these patients will benefit from the treatment. It is therefore of vital importance that the BRAF analysis is reliable and reflects the true nature of the tumour. Intraindividual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to BRAF gene
Share to Incidence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 28623774
DOI: 10.1016/j.ejca.2017.05.015

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis.PMID 28623774Read ↗

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.Semantic proximity Read ↗

BRAF Heterogeneity in Melanoma.Semantic proximity Read ↗

Controversies in Intrapatient Melanoma BRAFV600E Mutation Status.Semantic proximity Read ↗

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.Semantic proximity Read ↗

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.Semantic proximity Read ↗

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.Semantic proximity Read ↗

Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.Semantic proximity Read ↗

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutationsSemantic proximity Read ↗

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.Semantic proximity Read ↗

Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.Semantic proximity Read ↗

[BRAF mutation evolution in melanoma: Myth or reality?]Semantic proximity Read ↗

BRAF V600E Mutation in Malignant Melanoma-A Romanian Research Experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.